Binetrakin

At the 44th Annual Fall Clinical Dermatology Conference, Shawn Kwatra, MD, discussed the connection between prurigo nodularis, atopic dermatitis, and itch, highlighting shared pathophysiology and cytokines like IL-4, IL-13, and IL-31. This understanding has led to the approval of treatments like dupilumab and nemolizumab for both conditions. Kwatra also noted advancements in nonsteroidal topical therapies and new biologics targeting IL-4 receptor alpha, IL-13, and IL-31.

Shawn Kwatra, MD, emphasized the importance of asking patients about itch severity, discussed shared pathophysiology in atopic dermatitis (AD) and prurigo nodularis (PN), highlighted recent FDA approvals (dupilumab, lebrikizumab, nemolizumab), advocated for standardized itch assessment, and promoted non-steroidal topicals to avoid steroid-related adverse effects.

Dupixent significantly reduced itch and hive activity in uncontrolled chronic spontaneous urticaria patients, with 41% achieving well-controlled disease status. Positive Phase 3 LIBERTY-CUPID Study C data support potential U.S. regulatory resubmission by year-end, aiming for Dupixent to be the first new targeted treatment for CSU in over 10 years.

Regeneron and Sanofi present positive Phase 3 LIBERTY-CUPID Study C data on Dupixent in biologic-naïve CSU patients, showing significant itch and urticaria activity reduction and higher disease control rates compared to placebo, presented at ACAAI 2024.

Regeneron and Sanofi won FDA approval for Dupixent in COPD, targeting 300,000 U.S. adults with eosinophilic phenotype. GlobalData forecasts $6.57 billion in 2033 sales, while Sanofi and BMO Capital Markets predict $5.5 billion and $2.5 billion respectively. Competitors AstraZeneca, GSK, and Roche have ongoing trials for their biologics in COPD. Regeneron and Sanofi aim to establish market presence before rivals launch.

COPD treatment advances include precision medicine, biologics like dupilumab, biomarkers for early diagnosis, remote monitoring, omics tech, and regenerative medicine, promising more personalized and effective care.

Eli Lilly’s Ebglyss (lebrikizumab) approval in the US positions it competitively in the atopic dermatitis market, offering a therapeutic option for patients with limited success from existing treatments. Ebglyss selectively targets IL-13, potentially providing equal or superior long-term efficacy with less frequent dosing compared to Dupixent and Adbry/Adtralza. Its success will depend on differentiation, strategic positioning, and real-world clinical benefits.

Arginase is highly expressed in various tumors, and PG, an arginase inhibitor, shows anticancer potential by reducing cell invasion and promoting cell death. PG/ICG@MPs, microparticles loaded with PG and ICG, demonstrate precise tumor targeting and photothermal effects, effectively inhibiting ARG1 and activating iNOS to generate NO and ROS, thereby repolarizing TAMs to M1-like macrophages and enhancing tumor immunity. In vivo studies confirm PG/ICG@MPs' ability to inhibit tumor growth without significant toxicity.

15 participants (5 females, 10 males) showed varying degrees of urinary protein reduction post-treatment; 6 with >50% decrease, 9 with <50%. Mean 24-h urinary protein quantification pre-enrollment was 1.15 ± 0.94 g/day. Gastrointestinal symptoms improved in all post-treatment. 24-h urinary protein quantification decreased significantly at 1 and 3 months post-FMT, excluding 2 with acute infections. Specific urinary proteins and most immune cells/cytokines showed no significant changes. B cell counts decreased significantly post-FMT. Safety indicators showed no significant changes except for serum sodium and calcium. No severe adverse events reported. Gut microbiota composition changed post-FMT, with correlations noted between specific bacteria and B cell changes. Intestinal metabolite composition also changed, with correlations found between specific metabolites and B cells, serum calcium, and sodium.

FDA approves Dupixent for COPD, offering a new biologic treatment option for 300,000 U.S. adults with inadequately controlled COPD and eosinophilic COPD. Dupixent, a monoclonal antibody, reduces flare-ups, improves lung function, and enhances quality of life. Common side effects include injection-site reactions and viral infections.